DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER).

How it works

Dextrose is a monosaccharide that serves as a caloric agent and increases osmotic pressure to facilitate ultrafiltration during peritoneal dialysis. The osmotic gradient created by dextrose drives the removal of waste products and excess fluid from the blood across the peritoneal membrane.

What the body does with it

Metabolism	Dextrose is metabolized primarily via glycolysis and the Krebs cycle. In peritoneal dialysis, absorbed dextrose is systemically metabolized, primarily in the liver, to carbon dioxide and water, or stored as glycogen.
Excretion	Renal: 100% (dextrose is fully metabolized; water and electrolytes are removed via peritoneal dialysis, not excreted unchanged).
Half-life	Not applicable; dextrose is rapidly metabolized with a half-life of minutes; peritoneal dialysis dwell time is typically 4-6 hours.
Protein binding	Deferoxamine: not applicable; dextrose is not protein-bound.
Volume of Distribution	Not applicable; dextrose distributes throughout total body water (approx. 0.6 L/kg) but is rapidly metabolized.
Bioavailability	Intraperitoneal: 100% (dextrose is absorbed into systemic circulation).
Onset of Action	Intraperitoneal: ultrafiltration begins within 30 minutes of instillation.
Duration of Action	Intraperitoneal: 4-6 hours (clinical effect of fluid and solute removal during dwell time).

Classification & Brands

Dosing & administration

Intraperitoneal administration: 2 L (or appropriate volume based on body size) infused over 10-20 minutes, dwell time 4-6 hours, then drain; typically 4 exchanges per 24 hours.

Dosage form	SOLUTION
Renal impairment	No adjustment required as drug is administered intraperitoneally for peritoneal dialysis; dosing based on residual renal function and adequacy of dialysis.
Liver impairment	No specific adjustment; dextrose metabolism is not significantly altered in hepatic impairment.
Pediatric use	Weight-based: 30-40 mL/kg per exchange, with dwell time 4-6 hours; frequency typically 4-5 exchanges per day, adjusted for clinical status and ultrafiltration needs.
Geriatric use	Same as adult dosing but monitor for fluid and electrolyte imbalances; consider lower initial fill volumes (1.5-2 L) and adjust based on tolerance and clearance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER).

Breastfeeding	Minimal systemic absorption; no M/P ratio available. Considered compatible with breastfeeding; low risk to infant.
Teratogenic Risk	No teratogenic risk expected; dextrose and electrolytes are endogenous substances. No known fetal harm from peritoneal dialysis solutions.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None (not FDA-regulated as a drug; considered a medical device/solution. However, peritoneal dialysis solutions carry risks of peritonitis, fluid imbalance, and catheter complications.)

Side Effect Profile

Serious Effects

Absolute Contraindications

["Pre-existing severe hyperglycemia or diabetic ketoacidosis","Documented allergy or hypersensitivity to dextrose, electrolytes, or components","Abdominal conditions compromising peritoneal integrity (e.g., recent abdominal surgery, adhesions, bowel perforation, active peritonitis)","Severe pulmonary disease with impaired respiratory function due to intra-abdominal pressure","Chronic or recurrent peritonitis","Unable or unwilling to perform dialysis exchanges as prescribed"]

Clinical Precautions

Precautions

["Monitor for peritonitis, catheter exit-site infections, and tunnel infections","Risk of fluid overload or dehydration (closely monitor fluid balance)","Hyperglycemia and hyperosmolarity (especially in diabetic patients)","Electrolyte imbalances (e.g., hypokalemia, hypernatremia)","Mechanical complications (e.g., catheter obstruction, leakage, hernia)","Encapsulating peritoneal sclerosis (rare but serious)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Dextrose is metabolized primarily via glycolysis and the Krebs cycle. In peritoneal dialysis, absorbed dextrose is systemically metabolized, primarily in the liver, to carbon dioxide and water, or stored as glycogen.
Excretion	Renal: 100% (dextrose is fully metabolized; water and electrolytes are removed via peritoneal dialysis, not excreted unchanged).
Half-life	Not applicable; dextrose is rapidly metabolized with a half-life of minutes; peritoneal dialysis dwell time is typically 4-6 hours.
Protein binding	Deferoxamine: not applicable; dextrose is not protein-bound.
Volume of Distribution	Not applicable; dextrose distributes throughout total body water (approx. 0.6 L/kg) but is rapidly metabolized.
Bioavailability	Intraperitoneal: 100% (dextrose is absorbed into systemic circulation).
Onset of Action	Intraperitoneal: ultrafiltration begins within 30 minutes of instillation.
Duration of Action	Intraperitoneal: 4-6 hours (clinical effect of fluid and solute removal during dwell time).

Classification & Brands

Dosing & administration

Intraperitoneal administration: 2 L (or appropriate volume based on body size) infused over 10-20 minutes, dwell time 4-6 hours, then drain; typically 4 exchanges per 24 hours.

Dosage form	SOLUTION
Renal impairment	No adjustment required as drug is administered intraperitoneally for peritoneal dialysis; dosing based on residual renal function and adequacy of dialysis.
Liver impairment	No specific adjustment; dextrose metabolism is not significantly altered in hepatic impairment.
Pediatric use	Weight-based: 30-40 mL/kg per exchange, with dwell time 4-6 hours; frequency typically 4-5 exchanges per day, adjusted for clinical status and ultrafiltration needs.
Geriatric use	Same as adult dosing but monitor for fluid and electrolyte imbalances; consider lower initial fill volumes (1.5-2 L) and adjust based on tolerance and clearance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER).

Breastfeeding	Minimal systemic absorption; no M/P ratio available. Considered compatible with breastfeeding; low risk to infant.
Teratogenic Risk	No teratogenic risk expected; dextrose and electrolytes are endogenous substances. No known fetal harm from peritoneal dialysis solutions.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None (not FDA-regulated as a drug; considered a medical device/solution. However, peritoneal dialysis solutions carry risks of peritonitis, fluid imbalance, and catheter complications.)